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Abstract. Aim: To evaluate once-weekly hypofractionated
radiotherapy in elderly patients affected by early breast
cancer, reporting acute and late toxicity profiles, and
treatment feasibility. Patients and Methods: Fifty patients
were treated with a hypofractionated regimen: 28.5±2.5 Gy
in five fractions at one fraction weekly. Simultaneous
integrated boost (SIB) to the tumor bed in high-risk cases.
Inclusion criteria: patients over 70 years old, pT1-2, N0-1a.
Acute and late toxicities were assessed based on Radiation
Therapy Oncology Group. Results: The median follow-up
was 20 months and the median patient age was 79 years. SIB
was added for 22 patients (44%). Grade 3-4 acute cutaneous
toxicities were not observed; grade 2 toxicity occurred only
in four patients (8%). Late subcutaneous tissue toxicity
consisted of grade 2 fibrosis in two patients (4%), grade 1
in five (10%) and grade 0 in 41(85%). Conclusion: Limiting
fraction numbers with a safer profile may improve the
management of breast cancer for the elderly.
Breast cancer is the most common type of cancer affecting
females worldwide (1). About one-half of all newly
diagnosed breast cancer cases occur in women older than 65
years (2). Several randomized clinical trials and meta-
analyses have demonstrated that adjuvant radiotherapy plays
a fundamental role in reducing the risk of tumor recurrence
and improving survival (3). The standard recommended
radiation dose is 50 Gy in 25 fractions of 2 Gy, five times
per weeks, with a boost of 10 to 16 Gy to the tumor bed (4).
This fractionation of radiation dose lasts 6 weeks and may
be challenging in the elderly.
Nowadays, the use of hypofractionated schemes has
become increasingly common, achieving a shorter treatment
course, lower treatment costs, and shorter radiation therapy
waiting times (4-6). Several trials in the literature
demonstrated the efficacy and safe of hypofractionated
radiation therapy (7, 8). The START A and B trials (9, 10)
and the Canadian Trial (4) showed comparable results
between the hypofractionated schemes and the conventional
one. Finally, the UK FAST trial, a randomized trial,
compared two different regimens of hypofractionated
radiotherapy (28.5 Gy in five fractions and 30 Gy in five
fractions over 5 weeks) versus conventional radiotherapy,
showing comparable outcomes (7). 
In studies of elderly patients diagnosed with breast cancer,
the impact of aging and the increased likelihood of
concomitant comorbidity should be taken into account (11).
The omission of postoperative radiotherapy in the elderly is
still a matter of debate (12). 
In a comprehensive cohort study about patient compliance
with adjuvant standard breast radiation treatment, Harun et al.
found significant correlation between noncompliance and
unceasing patient age (p<0.0005) may be due to comorbidities
and low radiotherapy tolerance of elderly patients. This
evidence suggests that an improvement is needed because the
omission of radiation treatment results in a higher local failure
rate, and means a worse clinical outcome (13).
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Several studies investigated the effect of omission of
whole-breast radiotherapy in elderly women to assess the
impact on local control and low risk of local recurrence at 5
years (14, 15). Indeed, there is an increasing interest in
identifying a subgroup of patients with favorable prognostic
factors (node-negative, hormone-sensitive, low-grade,
negative surgical margins) for whom radiation therapy may
be avoided without compromising outcomes (14, 16, 17).
According to Kunkler et al., there is still no subgroup of
elderly in whom adjuvant radiotherapy can be systematically
omitted after breast-conserving surgery, and shortened
(hypofractionated) dose fraction schedules may be more
convenient for older patients, as supported by level 1
evidence (17). A short fractionation schedule, in fact, appears
promising to ensure control of residual cancer cells after
surgery in elderly women, who may have hindrances
attending hospital several times. 
Here we report our experience by testing this ‘innovative’
fractionation approach in clinical practice. An intensification
of radiation dose was also planned in selected women at high
risk of recurrence. This was a retrospective mono-
institutional study, the endpoint of which was to evaluate the
treatment feasibility and safety, concerning acute and
subacute skin toxicity, late tissue toxicity and clinical
outcomes. It is the first report of the use of a once-weekly
hypofractionated schedule with the addition of a
simultaneous integrated boost (SIB); to our knowledge, no
similar once-weekly regimen has been published, all the
previous studies which included the addition of a boost
analyzed the use of a sequential one.
Patients and Methods
Only patients with tumor <pT2 and <pN1a, aged over 70 years
(median age 79 years, range=72-90 years), with no severe
comorbidities, such as high-severity heart disease, cardiac arrest,
congestive heart failure, chronic obstructive pulmonary disease, and
with performance status (PS) 0-2, and no cognitive impairment,
were enrolled in this study. All the patients gave their written
informed consent to participation and use of data. 
A hypo-fractionation regimen was prescribed of 28.5 Gy in five
fractions, one fraction weekly, plus an intensification of radiation
dose by SIB. The SIB consisted of the delivery of 2.5 Gy (0.5 Gy
each fraction) to the tumor bed, in high-risk cases (22/50, 44%),
according to high grading (G3), positive margins, and unfavorable
biological pattern (hormone-receptor-negative, triple-negative or
human epidermal growth factor receptor 2 (HER2)-positive disease,
Ki-67 ≥20%). 
Planning parameters and treatment techniques. A planning
computed tomographic (CT) scan was scheduled for each patient.
Patients were positioned on a wing-board with both arms raised
above the head. All CT scans were performed from the level of the
larynx to the level of the upper abdomen, including both lungs, with
a scan thickness and index of 5 mm. A radiopaque wire was placed
encompassing the breast circumferentially for clinical reference.
Furthermore, four tattoos were marked in the supine position (two
on the sternal midline and one on each axillary midline) to ensure
the reproducibility of the setup (18).
The CT data were transmitted to an Eclipse Treatment Planning
System (Varian, Palo Alto, CA, USA). The clinical target volume
(CTV) included all the glandular breast tissue of the ipsilateral
breast and, where prescribed to the lumpectomy cavity, the SIB,
guided by the presence of surgical clips, as well as by hematoma,
seroma or other surgery-induced changes. The planning target
volume (PTV) consisted of 5 mm expansion of the CTV in all
directions except the skin. The structures outlined (organs at risk,
OARs) included the heart, the left anterior descending coronary
artery (LADCA), and ipsilateral lung (18).
The treatment was delivered in the supine position, with step-and-
shoot 3D-conformal radiation therapy. For whole-breast irradiation,
tangential field 3D-conformal radiation therapy was sufficient to
obtain qualitative dosimetry. The dose was prescribed to the PTV. 
Previous experience, for example, the START trial (9), considered
use of a breast cancer α/β ratio lower than the traditional value for
tumor cells of 10 Gy, but similar to that of experimental evidence
with a value between 4.0 and 4.6 Gy, for the sensitivity of breast
cancer to fractionation in the adjuvant setting (19, 20). According to
the linear-quadratic model (19), we used the following schedule [the
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Table I. Radiation Therapy Oncology Group classification of skin and subcutaneous tissue toxicity after radiotherapy (22). 
                                                                                                                                               RTOG grade
                                                                  1                                                         2                                                         3                                            4
Acute skin criteria         Follicular, faint or dull erythema/         Tender or bright erythema,           Confluent, moist desquamation          Ulceration, 
                                            epilation/dry desquamation/             patchy moist desquamation,                  other than skin folds,                 hemorrhage, 
                                                   decreased sweating                             moderate edema                                   pitting edema                            necrosis
Late skin criteria                Slight atrophy; pigmentation              Patch atrophy; moderate                         Marked atrophy; 
                                                change; some hair loss                telangiectasia; total hair loss                    gross telangiectasia                     Ulceration
Late subcutaneous              Slight induration (fibrosis)                  Moderate fibrosis but                       Severe induration and                    Necrosis
tissue criteria                     and loss of subcutaneous fat              asymptomatic; slight field                     loss of subcutaneous 
                                                                                                              contracture; <10%                         tissue; field contracture 
                                                                                                                linear reduction                         >10% linear measurement
α/β ratio of the START Trial (9)]: biologically effective dose
(BED)=nd (1+d/α/β)=5×5.7(1+5.7/4.6)=28.5×2.24=63.84 Gy, where
n was the number of treatment fractions, and d was the dose per
fraction in Gy. For the SIB volume (when applicable), the dose was
calculated as: BED=5×6.2(1+6.2/4.6)=31×2.35=72.7 Gy, which
provided a strong and acceptable adjuvant biological dosage.
Because of this relationship, if the estimated α/β value decreases,
the BED value increases. For the OARs of the left side (heart and
LADCA), doses were calculated considering values of α/β for the
heart of 2.5 Gy and for the LADCA of 1.7 Gy. Regarding OARs,
according to Nielsen et al. heart V20<10%, lung V20<25% and V20
of 0 for LADCA are constraints to be respected (21). V20 was
translated to V12 for radiobiological calculation, considering the
hypofractionated schedule. The field-in-field technique was used to
increase dose distribution homogeneity. Contralateral breast doses
were kept as low as possible, but in cases of conflict between
heart/lung dose versus contralateral breast, the heart dosage was
given priority for these elderly patients. 
Radiation treatment was delivered over 5 weeks, once weekly.
Each 5.7 Gy fraction plus SIB in high-risk patients was preceded
by verification of radiological positioning.
Acute and late toxicity assessment. The primary endpoints of this
analysis were acute skin toxicity and late skin and subcutaneous
tissue toxicity, and clinical outcomes (remarkable changes in breasts
appearance). Side-effects were evaluated according to Radiation
Therapy Oncology Group (RTOG) scale (Table I) (22);
desquamation was scored as none, dry, or moist. Edema, pain,
pruritus, and fatigue were also registered. These features were
assessed before radiotherapy, during each fraction, at the end of
radiotherapy, and at 2 and 4 weeks after treatment. Long-term
follow-up in the Radiation Therapy Department was limited to 6
months in the first year and every 12 months thereafter, to limit the
additional burden of consultations for this specific patient group.
Chi-squared test was used to indicate the independence of
toxicity from other variables (especially the SIB dosage) with a
significance level of p=0.05. 
Results
Clinical results. Between October 2016 and June 2017, 50
female patients with breast cancer were evaluated as being
eligible for adjuvant hypo-fractionated radiotherapy,
according to clinical characteristics (<pT2 and <pN1a, age
over 70 years), patient willingness and performance status.
Among 50 women selected, treatment was administered to
48; one patient died from thoracic aortic aneurysm fissure,
before beginning radiotherapy (no cancer- nor treatment-
related death); radiotherapy was interrupted for another
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Table II. Study patient characteristics.
Characteristic                                                                      Value
Age, years
  Median (range)                                                            79 (72-90)
  ≤80 Years, n (%)                                                        26/50 (56%)
  >80 Years, n (%)                                                        22/50 (44%)
Histology (ductal carcinoma), n (%)
  Invasive                                                                      48/50 (96%)
  In situ                                                                            2/50 (4%)
Pathological tumor stage, n (%)
  pTis-pT1                                                                     43/50 (86%)
  pT2                                                                              7/50 (14%)
Tumor size
  Median (range), cm                                                  1.25 (0.5-3.5)
Pathological nodal stage, n (%)
  pN0                                                                             45/50 (90%)
  pN1a                                                                            5/50 (10%)
Grading, n (%)
  G1                                                                                7/50 (14%)
  G2                                                                               38/50 (76%)
  G3                                                                                5/50 (10%)
Biology, n (%)
  Luminal A                                                                  41/50 (82%)
  Luminal B                                                                    2/50 (4%)
  HER2+                                                                          2/50 (4%)
  Triple-negative                                                             3/50 (6%)
  pTis                                                                               2/50 (4%)
Hormone therapy (luminal A/B), n (%)
  Aromatase inhibitor                                                  41/43 (95%)*
  Tamoxifen                                                                    2/43 (5%)
Breast size, n (%)
  Median volume (range), cm3                            553.95 (195.6-1001.1)
  1˚-3˚, n (%)                                                                23/50 (46%)
  4˚-7˚, n (%)                                                                27/50 (54%)
Laterality, n (%)
  Left                                                                             30/50 (60%)
  Right                                                                           20/50 (40%)
HER2: Human epidermal growth factor receptor 2. *One refusal.
Table III. Dosimetric results. 
Parameter                                                                     Result
Breast coverage 
  ≥95%                                                            Satisfied for all plans
SIB coverage
  ≥95%                                                            Satisfied for all plans
Breast PTV volume
  Median (range), cm3                                   553.95 (195.6-1001.1)
SIB volume
  Median (range), cm3                                     52.95 (20.8-149.4)
Heart (left side)
  Median Dmax (range), Gy                                14.60 (3.8-26.1)
  Median Dmean (range), Gy                                  0.8 (0.2-2.2
LADCA (left side)
  Median Dmax (range), Gy                                11.45 (3.8-17.2)
  Median Dmean (range), Gy                                2.65 (1.4-7.8)
Lung
  Median Dmax (range), Gy                               28.65 (25.6-32.1)
  Median Dmean (range), Gy                                3.15 (1.1-8.5)
SIB: Simultaneous integrated boost; LADCA: left anterior descending
coronary artery; PTV: planning target volume; Dmax: maximum dose;
Dmean: mean dose.
patient after three fractions at the patient’s request, against
physicians’ advice.
The median follow-up time was 20 months and the median
overall treatment time was 27 days (range=26-43 days). 
Clinical characteristics analyzed were tumor stage (T1-2),
nodal status (N0 -1a), grading (G1-3), HER2 expression (two
patients HER2 3+), proliferative index (33 patients Ki-67
<20% vs. 15 patients Ki-67>20%), histological type [invasive
ductal carcinoma 48/50 (96%), and ductal carcinoma in situ:
2/50 (4%)], hormonal status, and systemic therapy, laterality
and size (overall medium). As regards nodal involvement, five
patients had positive sentinel lymph nodes, two of them had
only one micrometastasis, and the other three patients
underwent nodal dissections, which were negative in all cases.
According to immunohistochemistry data, patients’ node-
negative, hormone receptor-positive, low Ki-67 value and
negative HER2, 43 patients underwent adjuvant hormonal
therapy; only one patient (2%) also underwent adjuvant
chemotherapy (taxol once weekly for 12 weeks); the remaining
ones did not have systemic therapy due to their age (Table II).
To date, all treated patients are alive and free of local
recurrence.
Dosimetric results. Good agreement with planning dosimetry
constraints was found, with constraints to thoracic OARs
(heart, LADCA, ipsilateral lung) according to Nielsen et al.
(21) being respected. For left-sided cases, the median
maximum (Dmax) and median mean (Dmean) doses were 14.6
and 0.8 Gy to the heart, 11.45 and 2.65 Gy to the LADCA,
and 28.65 and 3.15 Gy to both sides of the lung, respectively,
as reported in Table III.
For the LADCA, we obtained “translation” of conventional
fractionation constraint (V20) with radiobiological calculation
as V12 and this was 0 for all patients, except one due to
anatomical conformity, for whom LADCA Dmax was 17.2,
but we consider that this still respected the conventional
fraction constraint (V20=0). 
SIB technique (Figure 1) was used in 22/50 (44%) cases
and consisted of 0.5 Gy administered simultaneously to the
tumor bed in addition to the PTV dose, at each fraction. The
SIB volume was another CTV, and the sum-plan was
considered acceptable with V12 LADCA of 0. A criterion of
95% coverage of the breast PTV and SIB PTV receiving the
95% of the prescribed dose was satisfied for all plans. The
median breast volume was 553.95 cm3, and median SIB
volume was 52.95 cm3 (Table III).
Acute skin toxicity. Patients were visited during weekly
radiotherapy, at the end of treatment and subsequently and
evaluated according to RTOG scale (22). Clinically relevant
dermatitis and moist desquamation were uncommon; grade
3 and 4 dermatitis were not observed. At the end of
radiotherapy, 4/48 (8%) patients showed grade 2 toxicity and
were successfully treated with topical steroid in the
subsequent 2-3 weeks; 17/48 (35%) patients had grade 1
erythema; 27/48 (56%) women had no clinical side-effects.
Of these, 2 weeks after radiotherapy only 15 patients (31%)
manifested residual grade 1 toxicity and none after 1 month,
as illustrated in Figure 2.
To investigate the potential correlation between acute
toxicity and SIB administration, we performed a Chi-squared
test, and it demonstrated the independence of these variables
(p=0.05). 
Furthermore, in addition to minimal acute toxicity, clinical
outcomes were encouraging: 40/48 patients (83%) had good
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Figure 1. Example of simultaneous integrated boost dose distribution in
irradiation of the left breast.
Figure 2. Acute skin toxicity experienced by study patients graded
according to Radiation Therapy Oncology Group Scale (see Table I).
RT: Radiotherapy.
clinical and cosmetic results, with no remarkable change in
breast appearance, while 7/48 (15%) and 1/48 (2%) had
acceptable and poor cosmetic outcomes, respectively. 
Cutaneous acute toxicity was equally distributed on both
breast sides and did not correlate with laterality or quadrant
(by chi-squared test), with toxicity (G1 and G2 combined) at
the end of radiotherapy in 36% of left-sided cases, and 50%
of right-sided. Furthermore, the 20-month follow-up showed
the once-weekly regimen to be a feasible treatment with a
very low late toxicity rate and good clinical outcomes.
Late skin and subcutaneous tissue toxicity. Subcutaneous
tissue toxicity was evaluated 20 months after treatment. The
most common adverse event consisted in induration of the
breast, defined as hardening of the tissue, and was used to
assess fibrosis grade. Fibrosis grade 2 occurred only in two
patients (4%), grade 1 in five women (10%) and most of the
patients, 41(85%), had no late event. Furthermore, regarding
late skin toxicity, only one patient (2%) developed grade 1
hyperpigmentation, limited to the surgical scar area. Esthetic
outcomes were good to excellent in 94% and fair to poor in
6%. At the last follow-up, all patients were satisfied by this
short-course radiation regimen according to the low
incidence of adverse events and good outcomes. 
Discussion
Undertreatment in the elderly affects local control and disease-
free survival, especially in the intermediate- and high-risk
groups (23). Hancke et al. reported that standard radiotherapy
of female patients with breast cancer decreases substantially
for women aged 70 years and older; in particular, women of
this age often undergo recommended breast-conserving
therapy (70-79 years: 74%-83%; >79 years: 54%) (24). It is
well known that omission of adjuvant radiotherapy is related
to a higher risk of local recurrence. Therefore, it is important
to offer such treatment to all patients after breast-conserving
surgery, including the elderly (13, 25).
A shorter schedule may reduce the inconvenience
associated with numerous visits to the hospital and improve
the quality of life (26), particularly important for the elderly
given their difficulties in mobility, transportation, and even
in financial turns. Moreover, such a schedule results in
globally reducing treatment costs (27).
However, the feasibility and safety of accelerated
treatment needs validation before becoming the new gold
standard for early breast cancer care (28). Indeed, this
analysis was reserved for testing hypofractionation only for
women aged >70 years for whole-breast irradiation and SIB
technique for the high-risk group.
In 2017, Dragun et al. published a phase II trial of once-
weekly hypofractionated breast irradiation for 158 patients
with early breast cancer (28.5 or 30 Gy/five weekly fractions
+ boost), leading to good cosmetic results and with a median
follow-up 3 years (29).
Kirova et al. retrospectively compared an accelerated
weekly schedule (32.5 Gy/6.5 Gy) with normo-fractionation
in elderly patients and reported reassuring locoregional
control and cause-specific survival. Groups were not equally
balanced for age, performance status, tumor size, or presence
of lymph node dissection, disfavoring the accelerated
schedule. Lymph node irradiation and boost were limited to
the normo-fractionation group. However, this schedule was
an acceptable alternative to conventional treatment for
elderly patients. The 5- and 7-year local recurrence-free
survival rate was similar for the two groups: 95% and 93%
for the normo-fractionation group and 94% and 91% for the
one-weekly group (30).
A retrospective analysis of acceleration to five fractions in
patients aged 80 (57-89) years by Rovea et al. (27) (32.5
Gy/6.5 Gy or 30 Gy/6 Gy weekly) showed no toxicity in
71.8% and grade 1 in 22.6% of patients, with only 6.1%
clinically relevant dermatitis, as in our analysis. 
In 2005, Ortholan et al. reported on a weekly
hypofractionated schedule with a total dose of 32.5 Gy in
five fractions, once a week. Data for 150 patients aged >70
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Table IV. Weekly hypofractionated schedules for breast cancer reported in literature.
Author (Ref)                                                                     N                                                               Radiation therapy schedule
Agrawal  et al., 2011 (32)                                               915                              50 Gy (2 Gy × 25) versus 28.5 Gy (5.7 × 5) or 30 Gy (6 Gy × 5)
Rovea et al., 2015 (27)                                                   298                                                 30 Gy (6 Gy × 5) or 32.5 Gy (6.5 Gy × 5)
Brunt et al., 2016 (33)                                                    352                                   40 Gy in 15 sessions in 3 weeks versus 27 Gy in 5 sessions 
                                                                                                                                                in 1 week or 26 Gy in 5 sessions in 1 week
Dragun et al., 2017 (29)                                                 158                                          30 Gy (6 Gy × 5) or 28.5 Gy (5.7 Gy × 5) ±  boost 
                                                                                                                           10 Gy in 5 sessions or 8.1 Gy in 3 sessions or 5.7-6 Gy in 1 session 
Ortholan et al., 2005 (31)                                               150                                            6.5 Gy × 5; 5.5 Gy × 5; ± boost 6.5 Gy × 1 or 2 
Kirova et al., 2009 (30)                                                  367                                             32.5 Gy (6.5 Gy × 5) versus 50 Gy (2 Gy × 25)
Present study with dose intensification                            50                                                          28.5 (5.7 Gy × 5) ± SIB 0.5 Gy
SIB: Simultaneous integrated boost.
years who underwent conservative breast surgery (71.5%)
and mastectomy (28.5%), were analyzed. In 73.5% of
patients, no dermatitis was observed, and in the remainder,
it was limited to grade 1 and 2 in 18.6% and 9.4%,
respectively. This scheme resulted in mild early and late
toxicity and provide excellent local control (31).
The 2011 FAST trial, a phase III randomized clinical
trial of 915 patients with accrual between 2007 and 2011,
compared 50 Gy in 25 fractions (control group) versus 28.5
Gy or 30 Gy in five fractions, once weekly. The study
showed low rates of acute and late skin toxicity, concluding
that once-weekly hypofractionation (with a dose of 28.5
Gy) was feasible and safe. The 28.5 Gy schedule was the
same we used in our analysis, but in the FAST trial, no
boost dose to the tumor bed was administered in any
regimen. In our study, we adopted an intensified dose for
patients at high risk of recurrence by delivering an SIB
technique; this intensified dose did not appear to be
correlated with any increase of acute or late toxicity (32).
Other trials regarding late toxicity, cosmetic outcome, and,
above all, rates of ipsilateral breast tumor recurrence have
been undertaken or are ongoing [including FAST-Forward
Trial (33)] in order to confirm that the 1-week, 5-fraction
schedule is as effective and safe as the current regimen
(Table IV).
Besides low incidence of acute and late toxicity, the once-
weekly regimen increased treatment feasibility: among our
patients, radiation therapy was discontinued for only one
woman, and not for clinical reasons. Elderly patients often
present other comorbidities that may limit frequent access to
a hospital. In order to avoid poor adherence to adjuvant
radiotherapy, once-weekly hypofractionation should be
considered a valid treatment option. 
This hypo-fractionated schedule is proven to be a feasible
treatment, with minimal acute skin and late skin and
subcutaneous tissue toxicity, comparable with published data
on the other regimens. Moreover, dosimetric results were
satisfying and in accordance with the literature. This regimen
facilitates radiation treatment for elderly patients, who may
rarely attend hospital, by limiting the number of fractions
required and making this regimen safe.
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